- Home
- CHNR vs AZTR Comparison
CHNR vs AZTR Comparison
Compare CHNR & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- AZTR
- Stock Information
- Founded
- CHNR N/A
- AZTR 2014
- Country
- CHNR China
- AZTR United States
- Employees
- CHNR N/A
- AZTR N/A
- Industry
- CHNR Precious Metals
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- CHNR Basic Materials
- AZTR Health Care
- Exchange
- CHNR Nasdaq
- AZTR Nasdaq
- Market Cap
- CHNR 4.6M
- AZTR 4.0M
- IPO Year
- CHNR 1995
- AZTR 2023
- Fundamental
- Price
- CHNR $3.92
- AZTR $0.26
- Analyst Decision
- CHNR
- AZTR
- Analyst Count
- CHNR 0
- AZTR 0
- Target Price
- CHNR N/A
- AZTR N/A
- AVG Volume (30 Days)
- CHNR 150.4K
- AZTR 4.6M
- Earning Date
- CHNR 05-15-2025
- AZTR 08-11-2025
- Dividend Yield
- CHNR N/A
- AZTR N/A
- EPS Growth
- CHNR N/A
- AZTR N/A
- EPS
- CHNR N/A
- AZTR N/A
- Revenue
- CHNR N/A
- AZTR $7,500.00
- Revenue This Year
- CHNR N/A
- AZTR N/A
- Revenue Next Year
- CHNR N/A
- AZTR N/A
- P/E Ratio
- CHNR N/A
- AZTR N/A
- Revenue Growth
- CHNR N/A
- AZTR N/A
- 52 Week Low
- CHNR $3.57
- AZTR $0.23
- 52 Week High
- CHNR $9.04
- AZTR $12.00
- Technical
- Relative Strength Index (RSI)
- CHNR 44.82
- AZTR 45.07
- Support Level
- CHNR $3.66
- AZTR $0.25
- Resistance Level
- CHNR $4.30
- AZTR $0.27
- Average True Range (ATR)
- CHNR 0.68
- AZTR 0.02
- MACD
- CHNR -0.04
- AZTR -0.00
- Stochastic Oscillator
- CHNR 9.64
- AZTR 24.85
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.